In:
Antiviral Therapy, SAGE Publications, Vol. 11, No. 4 ( 2006-05), p. 439-445
Abstract:
Lopinavir is an HIV protease inhibitor that is co-formulated with ritonavir. The approved paediatric dose is 230/57.5 mg/m 2 twice daily. Once-daily dosing may offer an advantage to adherence. We studied the pharmacokinetics of lopinavir/ritonavir in a once-daily regimen in HIV-1-infected children. Methods HIV-1-infected children on stable antiretroviral therapy with a viral load 〈 50 copies/ml for at least 6 months received lopinavir/ritonavir 460/115 mg/m 2 once daily with zidovudine and lamivudine. Blood samples were collected at 0, 2, 4, 6, 8, 12, 18 and 24 h after observed intake during steady state. Target level for lopinavir C min was 1.0 mg/l, based on in vitro IC 50 data. Results Nineteen HIV-1-infected children with a median (range) age of 4.5 (1.4–12.9) years were enrolled. The median (interquartile range) dose of lopinavir was 456 (444–477) mg/m 2 . The mean (standard deviation) AUC 0–24 , C max and C min of lopinavir were 149.8 ±58.8 h*mg/l, 10.77 ±2.90 mg/l and 2.88 ±3.74 mg/l respectively. These values are comparable to data observed in adults using lopinavir/ritonavir 800/200 mg once daily. In 10/19 (53%) children C min was considered to be too low ( 〈 1.0 mg/l). Younger children more often experienced subtherapeutic trough levels. Conclusion Our findings indicate that 460/115 mg/m 2 lopinavir/ritonavir once daily leads to mean pharmacokinetic parameters comparable to data of 800/200 mg lopinavir/ritonavir once daily in adults, although the variability observed in the trough levels is much higher in children. Further research, especially in young children, is necessary to determine whether a higher dosage of lopinavir/ritonavir once daily must be given to reach the target level for C min .
Type of Medium:
Online Resource
ISSN:
1359-6535
,
2040-2058
DOI:
10.1177/135965350601100412
Language:
English
Publisher:
SAGE Publications
Publication Date:
2006
detail.hit.zdb_id:
2118396-X
SSG:
15,3
Permalink
